KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Net Income towards Common Stockholders (2016 - 2026)

Pacific Biosciences Of California has reported Net Income towards Common Stockholders over the past 16 years, most recently at -$40.4 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 1802.7% year-over-year to -$40.4 million; the TTM value through Dec 2025 reached -$546.4 million, down 76.34%, while the annual FY2025 figure was -$546.4 million, 76.34% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$40.4 million at Pacific Biosciences Of California, down from -$38.0 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $2.4 million in Q4 2024 and troughed at -$426.1 million in Q1 2025.
  • A 5-year average of -$85.4 million and a median of -$69.8 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: skyrocketed 102.89% in 2024 and later plummeted 1802.7% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$69.3 million in 2021, then decreased by 21.72% to -$84.4 million in 2022, then grew by 2.8% to -$82.0 million in 2023, then skyrocketed by 102.89% to $2.4 million in 2024, then plummeted by 1802.7% to -$40.4 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for PACB at -$40.4 million in Q4 2025, -$38.0 million in Q3 2025, and -$41.9 million in Q2 2025.